R. Lor Randall, MD, FACS

R. Lor Randall, MD, FACS, discusses the multidisciplinary nature of research aiming to develop a predictive model of sarcoma survivorship.

R. Lor Randall, MD, FACS, discusses the potential implications of research into how socioeconomic disparities and cancer biology impact long-term outcomes in pediatric sarcoma.

R. Lor Randall, MD, FACS, outlines the aims and phases of a prospective study evaluating outcome disparities in pediatric sarcoma survivorship care.

R. Lor Randall, MD, discusses the need to move beyond modest survival improvements in pediatric bone sarcoma toward equitable, precision survivorship care.

R. Lor Randall, MD, FACS, discusses a new STS surveillance algorithm based on findings that show the comparable diagnostic utility of ultrasound and MRI.

R. Lor Randall, MD, FACS, summarizes the current status of and future directions for imaging protocols for post-surgical extremity STS surveillance.

R. Lor Randall, MD, FACS, compares the diagnostic accuracy, recurrence detection rates, and cost effectiveness of MRI vs ultrasound STS surveillance.

R. Lor Randall, MD, FACS, discusses the current paradigm and future trajectory of imaging modalities for the surveillance of soft tissue sarcoma.

R. Lor Randall, MD, FACS, discusses the challenges associated with incorporating surgical protocols into clinical trials evaluating sarcoma treatments.

R. Lor Randall, MD, FACS, discusses future research directions for advancing prosthetic embodiment for patients with sarcoma undergoing amputation.

R. Lor Randall, MD, FACS, discusses the management of non-ossifying fibromas, and how this differs from that of malignant tumors.

R. Lor Randall, MD, FACS, discusses the complexity of perivascular epithelioid cell tumors and the critical importance of multidisciplinary care.

R. Lor Randall, MD, FACS, discusses how suboptimal access to multidisciplinary, coordinated care remains a critical barrier to optimal outcomes in sarcoma.

R . Lor Randall, MD, FACS, discusses disparities in global access to care for patients with sarcoma.

R. Lor Randall, MD, FACS discusses the evolving role of surgical management in patients with low-grade chondrosarcoma.

R. Lor Randall, MD, FASCO, discusses key areas of consensus discussed at the Annual Birmingham Orthopedic Oncology Meeting.

R. Lor Randall, MD, FASCO, discussed the development and application of three-dimensional spheroid models for high-throughput drug screening in osteosarcoma research.

R. Lor Randall, MD, FACS, discusses whether patients with low-grade chondosarcomas should undergo intralesional curettage or en bloc resection.

R. Lor Randall, MD, FACS, discusses the benefits of a 3-dimensional model of the sarcoma tumor microenvironment for studying metastasis control mechanisms.

R. Lor Randall, MD, FACS, discusses the value of collaboration between oncologists and biomedical engineers to develop preclinical sarcoma models.

Lor Randall, MD, FACS, on a global survey regarding enrollment criteria for a trial evaluating surgical resection for proximal femur metastases.

R. Lor Randall, MD, FACS, discusses how immunodeficient mouse models support mechanistic and therapeutic discovery in rare sarcoma subtypes.

Frozen section analysis may be better reserved for high-risk tumor resections, as routine use shows limited benefit and increases cost, survey suggests.

R. Lor Randall, MD, FACS, discusses the application of a bioengineered bone marrow matrix as a three-dimensional model to analyze osteosarcoma cell behavior under varying oxygen tensions.

R. Lor Randall, MD, FACS, discusses how to select between vimseltinib, pexidartinib, and surgery for patients with tenosynovial giant cell tumor.

R. Lor Randall, MD, FACS, discusses the utility of routine intraoperative frozen margin assessment in soft tissue sarcoma.

R. Lor Randall, MD, FACS, discusses the impact of race, ethnicity, and socioeconomic factors on outcomes in pediatric patients with nonmetastatic osteosarcoma.

R. Lor Randall, MD, FACS, discusses the role of EZH2 in doxorubicin resistance in soft tissue sarcoma.

R. Lor Randall, MD, FACS, discusses findings from a study of one-stage synovectomy in patients with diffuse-type tenosynovial giant cell tumor of the knee.

R. Lor Randall, MD, FACS, discusses the investigation of ganitumab plus standard-of-care interval-compressed chemotherapy in a phase 3 trial for newly diagnosed metastatic Ewing sarcoma.